Hypoparathyroidism historical perspective: Difference between revisions
Jump to navigation
Jump to search
| Line 16: | Line 16: | ||
==Landmark Events in the Development of Treatment Strategies== | ==Landmark Events in the Development of Treatment Strategies== | ||
*In 1925, James Bertram Collip along with Douglous B Leitch treated [[tetany]] with the help of [[Parathyroid gland|parathyroid]] extract. They names the extract as Parathyrin.<ref name="pmid20315252">{{cite journal |vauthors=Collip JB, Leitch DB |title=A Case of Tetany treated with Parathyrin |journal=Can Med Assoc J |volume=15 |issue=1 |pages=59–60 |year=1925 |pmid=20315252 |pmc=1707993 |doi= |url=}}</ref> | *In 1925, James Bertram Collip along with Douglous B Leitch treated [[tetany]] with the help of [[Parathyroid gland|parathyroid]] extract. They names the extract as Parathyrin.<ref name="pmid20315252">{{cite journal |vauthors=Collip JB, Leitch DB |title=A Case of Tetany treated with Parathyrin |journal=Can Med Assoc J |volume=15 |issue=1 |pages=59–60 |year=1925 |pmid=20315252 |pmc=1707993 |doi= |url=}}</ref> | ||
*In 2015, Use of rhPTH (1–84) for the management of hypoparathyroidism is approved by the U.S. Food and Drug Administration (FDA).<ref name="pmid26938200">{{cite journal |vauthors=Bilezikian JP, Brandi ML, Cusano NE, Mannstadt M, Rejnmark L, Rizzoli R, Rubin MR, Winer KK, Liberman UA, Potts JT |title=Management of Hypoparathyroidism: Present and Future |journal=J. Clin. Endocrinol. Metab. |volume=101 |issue=6 |pages=2313–24 |year=2016 |pmid=26938200 |pmc=5393596 |doi=10.1210/jc.2015-3910 |url=https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125511s000lbl.pdf}}</ref> | *In 2015, Use of rhPTH (1–84) for the management of hypoparathyroidism is approved by the U.S. Food and Drug Administration (FDA).<ref name="pmid26938200">{{cite journal |vauthors=Bilezikian JP, Brandi ML, Cusano NE, Mannstadt M, Rejnmark L, Rizzoli R, Rubin MR, Winer KK, Liberman UA, Potts JT |title=Management of Hypoparathyroidism: Present and Future |journal=J. Clin. Endocrinol. Metab. |volume=101 |issue=6 |pages=2313–24 |year=2016 |pmid=26938200 |pmc=5393596 |doi=10.1210/jc.2015-3910 |url=https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125511s000lbl.pdf}}</ref> | ||
Revision as of 17:56, 18 September 2017
|
Hypoparathyroidism Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Hypoparathyroidism historical perspective On the Web |
|
American Roentgen Ray Society Images of Hypoparathyroidism historical perspective |
|
Risk calculators and risk factors for Hypoparathyroidism historical perspective |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Overview
Historical Perspective
Discovery
- In 1852, Sir Richard Owen, Hunterian Professor and Conservator of the Museum in the Royal College of Surgeons of England, described parathyroids in rhinoceros.[1]
- In 1880, Ivar Sandström, a Swedish anatomist, described parathyroids in human following 50 autopsies. He found two parathyroid glands bilaterally in 43 out of 50 autopsies.[2]
- In 1909, William George MacCallum and Carl Voegtlin, demonstrated association between parathyroid gland, calcium, and tetany.[3]
- In 1942, Albright et. al. first described the term pseudohypoparathyroidism. It is an example of Seabright-Bantam syndrome. In pseudohypoparathyroidism hypocalcemia and hyperphosphatemia is resistant to parathyroid hormone administration.[4]
- In 1959, Howard Rasmussen and Lyman C. Craig at the Rockefeller Institute for Medical Research purified parathyroid hormone.[5] They also isolated the active polypeptide (parathormone B) from bovine parathyroid gland and gave its tentative formula in 1961.[6]
Landmark Events in the Development of Treatment Strategies
- In 1925, James Bertram Collip along with Douglous B Leitch treated tetany with the help of parathyroid extract. They names the extract as Parathyrin.[7]
- In 2015, Use of rhPTH (1–84) for the management of hypoparathyroidism is approved by the U.S. Food and Drug Administration (FDA).[8]
Impact on Cultural History
Famous Cases
- The following are a few famous cases of disease name:
References
- ↑ Modarai B, Sawyer A, Ellis H (2004). "The glands of Owen". J R Soc Med. 97 (10): 494–5. doi:10.1258/jrsm.97.10.494. PMC 1079622. PMID 15459265.
- ↑ Johansson H (2015). "The Uppsala anatomist Ivar Sandström and the parathyroid gland". Ups. J. Med. Sci. 120 (2): 72–7. doi:10.3109/03009734.2015.1027426. PMC 4463479. PMID 25913489.
- ↑ Maccallum WG, Voegtlin C (1909). "ON THE RELATION OF TETANY TO THE PARATHYROID GLANDS AND TO CALCIUM METABOLISM". J. Exp. Med. 11 (1): 118–51. PMC 2124703. PMID 19867238.
- ↑ Albright F, Burnett CH, Smith PH, Parson (1942). "Pseudohypoparathyroidism- An example of 'Seabright-Bantam syndrome'". Endocrinology. 30: 922–32.
- ↑ Rasmussen, Howard; Craig, Lyman C. (1959). "PURIFICATION OF PARATHYROID HORMONE BY USE OF COUNTERCURRENT DISTRIBUTION". Journal of the American Chemical Society. 81 (18): 5003–5003. doi:10.1021/ja01527a066. ISSN 0002-7863.
- ↑ Rasmussen, Howard; Craig, Lyman C. (1961). "Isolation of a Parathyroid Polypeptide from Acetic Acid Extracts of Bovine Parathyroid Glands". {Journal of Biological Chemistry. 236 (4): 1083–1086.
- ↑ Collip JB, Leitch DB (1925). "A Case of Tetany treated with Parathyrin". Can Med Assoc J. 15 (1): 59–60. PMC 1707993. PMID 20315252.
- ↑ Bilezikian JP, Brandi ML, Cusano NE, Mannstadt M, Rejnmark L, Rizzoli R, Rubin MR, Winer KK, Liberman UA, Potts JT (2016). "Management of Hypoparathyroidism: Present and Future" (PDF). J. Clin. Endocrinol. Metab. 101 (6): 2313–24. doi:10.1210/jc.2015-3910. PMC 5393596. PMID 26938200.